Want to see DWTX full AI Analyst Report?
DWTX Stock Chart & Stats
$2.66
$0.03(2.00%)
At close: 4:00 PM EDT
$2.66
$0.03(2.00%)
Day’s Range― - ―
52-Week Range$1.28 - $7.04
Previous Close$1.53
Volume4.55K
Average Volume (3M)70.53K
Market Cap
$51.67M
Enterprise Value$45.47M
Total Cash (Recent Filing)$9.61M
Total Debt (Recent Filing)$127.21K
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Nov 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.95
Shares Outstanding33,992,554
10 Day Avg. Volume60,886
30 Day Avg. Volume70,528
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.72K
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$13.50Price Target Upside407.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extremely Low LeverageExtremely low leverage limits refinancing and interest-burden risk, preserving financial flexibility relative to a highly indebted company. This gives Dogwood more capacity to direct available resources toward development activities and reduces balance-sheet pressure during periods of ongoing operating losses.
Governance ImprovementsApproved governance measures can strengthen the company’s operating framework and support more effective oversight as it develops its business. Better governance may improve strategic execution and stakeholder confidence over the next several quarters, although it does not by itself resolve the company’s funding needs.
Financing FlexibilityThe larger authorized-share capacity gives Dogwood an additional mechanism to pursue financing or strategic actions while it remains loss-making. That flexibility can help sustain development efforts and extend operations, though its value depends on management using the capacity prudently.
Bears Say
No Revenue And Widening LossesNo demonstrated revenue stream and materially widening losses indicate that Dogwood has not yet established commercial traction or earnings support. The higher loss profile raises the amount of capital required to reach potential commercialization and makes near-term profitability highly dependent on successful development progress.
Persistent Cash BurnSustained negative operating and free cash flow shows that the business is consuming funding rather than financing operations internally. Continued deterioration in cash generation can increase reliance on external capital, constrain development choices, and make financial stability more sensitive to fundraising conditions.
Equity Decline And Dilution RiskDeclining equity alongside ongoing losses indicates that the company is consuming shareholder capital, while expanded share authorization creates a route for future dilution. If losses persist, additional financing may reduce existing ownership interests and weaken per-share economic participation in future success.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.28 and its highest was $7.04 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $51.67M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 28 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.2.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,992,554 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.84%
12-Months-Change
Fundamentals
Return on Equity
-47.85%
Trailing 12-Months
Asset Growth
-16.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(407.52% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
72.79% Insiders
0.44% Mutual Funds
9.22% Other Institutional Investors
17.10% Public Companies and
Individual Investors